drugset / Trial / NCT00824473

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00824473

Phase 3 Completed 506 enrolled Meda Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if one allergy medication (0.15% azelastine hydrochloride) is more effective than Placebo alone

Timeline

Start
2008-12
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azelastine Small molecule 0.15 % Intranasal
Comparator Azelastine Small molecule 822 ug Intranasal